Risk factors for development of personal protective equipment induced headache: e-survey of medical staff in Baltic states.


Journal

BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677

Informations de publication

Date de publication:
10 Aug 2022
Historique:
received: 11 04 2022
accepted: 27 07 2022
entrez: 10 8 2022
pubmed: 11 8 2022
medline: 13 8 2022
Statut: epublish

Résumé

The COVID-19 pandemic led to an unprecedented increase in the use of personal protective equipment (PPE) among medical personnel. The goal of this study was to determine the risk factors and frequency of PPE-induced headache during the COVID-19 pandemic. From January 25 to March 1, 2021, an anonymous online survey was undertaken in the Baltic states. In total, 2132 individuals participated. 52.3% experienced a PPE-induced headache. Usual onset time was between 2-3 h, lasting up to 1 h after PPE removal. The most common localization was in temporal and frontal regions. Headache usually occurred 2 to 3 days per week with an average pain score of 5.04 ± 1.80 points. Higher risk was associated with discomfort/pressure OR = 11.55, heat stress OR = 2.228, skin conditions OR = 1.784, long PPE use (duration 10-12 h) OR = 2,18, headache history prior PPE use OR = 1.207. Out of 52.3% respondents with PPE-induced headache, 45.5% developed de novo headache, whereas 54.5% had headache history. Statistically significant differences of PPE-induced headache between respective groups included severity (4.73 vs 5.29), duration (≥ 6 h 6.7% vs 8.2%), accompanying symptoms (nausea (19.3% vs 25.7%), photophobia (19.1% vs 25.7%), phonophobia (15.8% vs 23.5%), osmophobia (5.3% vs 12.0%)) and painkiller use (43.0% vs 61.7%). Over half of the medical personnel reported headache while using PPE. The risk was higher in individuals with headache history, increased duration of PPE use and discomfort while using PPE. Predisposed individuals reported PPE-induced headache which persisted longer, was more intense and debilitating than in the respondents with de novo headache.

Sections du résumé

BACKGROUND BACKGROUND
The COVID-19 pandemic led to an unprecedented increase in the use of personal protective equipment (PPE) among medical personnel. The goal of this study was to determine the risk factors and frequency of PPE-induced headache during the COVID-19 pandemic.
METHODS METHODS
From January 25 to March 1, 2021, an anonymous online survey was undertaken in the Baltic states.
RESULTS RESULTS
In total, 2132 individuals participated. 52.3% experienced a PPE-induced headache. Usual onset time was between 2-3 h, lasting up to 1 h after PPE removal. The most common localization was in temporal and frontal regions. Headache usually occurred 2 to 3 days per week with an average pain score of 5.04 ± 1.80 points. Higher risk was associated with discomfort/pressure OR = 11.55, heat stress OR = 2.228, skin conditions OR = 1.784, long PPE use (duration 10-12 h) OR = 2,18, headache history prior PPE use OR = 1.207. Out of 52.3% respondents with PPE-induced headache, 45.5% developed de novo headache, whereas 54.5% had headache history. Statistically significant differences of PPE-induced headache between respective groups included severity (4.73 vs 5.29), duration (≥ 6 h 6.7% vs 8.2%), accompanying symptoms (nausea (19.3% vs 25.7%), photophobia (19.1% vs 25.7%), phonophobia (15.8% vs 23.5%), osmophobia (5.3% vs 12.0%)) and painkiller use (43.0% vs 61.7%).
CONCLUSIONS CONCLUSIONS
Over half of the medical personnel reported headache while using PPE. The risk was higher in individuals with headache history, increased duration of PPE use and discomfort while using PPE. Predisposed individuals reported PPE-induced headache which persisted longer, was more intense and debilitating than in the respondents with de novo headache.

Identifiants

pubmed: 35948960
doi: 10.1186/s12913-022-08412-5
pii: 10.1186/s12913-022-08412-5
pmc: PMC9363870
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1016

Informations de copyright

© 2022. The Author(s).

Références

Headache. 2011 Jun;51(6):839-42
pubmed: 21631471
Eur J Dent. 2020 Dec;14(S 01):S79-S85
pubmed: 33368069
Curr Pain Headache Rep. 2010 Aug;14(4):321-4
pubmed: 20499214
J Clin Neurosci. 2022 Mar;97:87-92
pubmed: 35066364
Am J Infect Control. 2021 Oct;49(10):1305-1315
pubmed: 33965463
Ir J Med Sci. 2021 Nov;190(4):1565-1569
pubmed: 33459943
Br J Surg. 2021 Dec 1;108(12):e411
pubmed: 34459864
Headache. 2020 May;60(5):864-877
pubmed: 32232837
J Headache Pain. 2020 Jan 14;21(1):5
pubmed: 31937239
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Am J Infect Control. 2013 Dec;41(12):1218-23
pubmed: 23768438

Auteurs

Mantas Jokubaitis (M)

Centre of Neurology, Vilnius University, Vilnius, Lithuania. mantas.jokubaitis1@gmail.com.

Reda Timofejavaitė (R)

Centre of Neurology, Vilnius University, Vilnius, Lithuania.

Mark Braschinsky (M)

Neurology Clinic, Tartu University Hospital, Tartu, Estonia.
Department of Neurology and Neurosurgery, University of Tartu, Tartu, Tartu, Estonia.

Linda Zvaune (L)

Department of Neurology and Neurosurgery, Riga East Clinical University Hospital, Riga, Latvia.

Alo-Rainer Leheste (AR)

Neurology Clinic, Tartu University Hospital, Tartu, Estonia.

Laura Gribuste (L)

Department of Neurology, Pauls Stradins Clinical University Hospital, Riga, Latvia.

Paula Mattila (P)

Faculty of Medicine, University of Tartu, Tartu, Estonia.

Sintija Strautmane (S)

Department of Neurology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Faculty of Residency, Riga Stradins University, Riga, Latvia.

Austėja Dapkutė (A)

Centre of Neurology, Vilnius University, Vilnius, Lithuania.

Kristina Ryliškienė (K)

Centre of Neurology, Vilnius University, Vilnius, Lithuania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH